<DOC>
	<DOCNO>NCT02857777</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics , safety , tolerability intranasally administer esketamine elderly Japanese subject healthy young adult Japanese subject .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability Study Intranasally Administered Esketamine Elderly Japanese , Healthy Younger Adult Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>A ) Cohort 1 : Be Japanese man woman great equal ( &gt; = ) 65 year age least 4 subject &gt; = 70 year age , born Japan , reside outside Japan &gt; = 10 year , parent maternal paternal grandparent Japanese ethnicity . Subjects must either healthy present stable , wellcontrolled , chronic condition frequently occur elderly , : Hyperlipidemia , Controlled hypertension , Impaired fast glucose , impair glucose tolerance , type 2 diabetes mellitus control diet , and/or metformin monotherapy , dipeptidyl peptidase4 ( DPP4 ) inhibitor monotherapy combination metformin DPP4 inhibitor , glycated hemoglobin ( HbA1c ) level &lt; 8 percent ( % ) , Degenerative joint disorder osteoporosis ; B ) Cohort 2 : Be healthy Japanese man woman 20 55 year age , inclusive , born Japan , reside outside Japan &gt; = 10 year , parent maternal paternal grandparent Japanese ethnicity . Each subject match elderly subject Cohort 1 gender body weight ( +/ 20 % ) use data collect Screening Signed inform consent document indicate understand purpose procedure require study willing participate study Willing adhere prohibition restriction specify protocol Cohort 2 : If woman , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen negative urine pregnancy test Day 1 treatment period . Women use contraceptive must agree use additional birth control method study 1 month receive last dose study drug If woman , must agree donate egg ( ovum , oocytes ) purpose assist reproduction Current significant psychiatric disorder include limited psychotic , bipolar , major depressive , anxiety disorder History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude subject could interfere interpretation study result . Elderly subject Cohort 1 stable , wellcontrolled , chronic condition frequently occur elderly outline Inclusion Criteria 1 permit participate study Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen Day 1 Period 1 deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) screen first study drug administration deem appropriate investigator History moderate severe use disorder accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSM5 ) criterion within 1 year screen positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , benzodiazepine ) screen Day 1 treatment period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>